Knight Therapeutics (TSE:GUD) Shares Down 0.2% – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) traded down 0.2% on Monday . The company traded as low as C$5.65 and last traded at C$5.70. 36,840 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 58,048 shares. The stock had previously closed at C$5.71.

Wall Street Analysts Forecast Growth

Separately, Raymond James upgraded Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th.

Knight Therapeutics Stock Performance

The company’s 50 day simple moving average is C$5.36 and its two-hundred day simple moving average is C$5.57. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. The stock has a market cap of C$581.96 million, a price-to-earnings ratio of -28.75, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Insider Buying and Selling

In related news, insider Sime Armoyan acquired 90,300 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of C$5.13 per share, for a total transaction of C$463,672.44. Also, Director Samira Sakhia bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of C$5.15 per share, for a total transaction of C$103,000.00. 45.62% of the stock is currently owned by corporate insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.